938 related articles for article (PubMed ID: 20061178)
21. Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein.
Huang X; Wong MK; Yi H; Watkins S; Laird AD; Wolf SF; Gorelik E
Cancer Res; 2002 Oct; 62(20):5727-35. PubMed ID: 12384531
[TBL] [Abstract][Full Text] [Related]
22. Tumor-associated angiogenesis: mechanisms, clinical implications, and therapeutic strategies.
Pluda JM
Semin Oncol; 1997 Apr; 24(2):203-18. PubMed ID: 9129690
[TBL] [Abstract][Full Text] [Related]
23. Anti-angiogenic strategies for cancer therapy (Review).
Benouchan M; Colombo BM
Int J Oncol; 2005 Aug; 27(2):563-71. PubMed ID: 16010440
[TBL] [Abstract][Full Text] [Related]
24. Pathogenesis of metastatic disease: implications for current therapy and for the development of new therapeutic strategies.
Poste G
Cancer Treat Rep; 1986 Jan; 70(1):183-99. PubMed ID: 3510734
[TBL] [Abstract][Full Text] [Related]
25. Single-agent and combination therapeutic strategies to inhibit hepatocyte growth factor/MET signaling in cancer.
Toschi L; Jänne PA
Clin Cancer Res; 2008 Oct; 14(19):5941-6. PubMed ID: 18829470
[TBL] [Abstract][Full Text] [Related]
26. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy.
Pastorino F; Brignole C; Marimpietri D; Cilli M; Gambini C; Ribatti D; Longhi R; Allen TM; Corti A; Ponzoni M
Cancer Res; 2003 Nov; 63(21):7400-9. PubMed ID: 14612539
[TBL] [Abstract][Full Text] [Related]
27. Persistent vascular normalization as an alternative goal of anti-angiogenic cancer therapy.
Sato Y
Cancer Sci; 2011 Jul; 102(7):1253-6. PubMed ID: 21401807
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of angiogenesis and the angiogenesis/invasion shift.
Bikfalvi A; Moenner M; Javerzat S; North S; Hagedorn M
Biochem Soc Trans; 2011 Dec; 39(6):1560-4. PubMed ID: 22103487
[TBL] [Abstract][Full Text] [Related]
29. Anti-angiogenic therapy: adapting strategies to overcome resistant tumors.
Mitchell DC; Bryan BA
J Cell Biochem; 2010 Oct; 111(3):543-53. PubMed ID: 20626031
[TBL] [Abstract][Full Text] [Related]
30. Combined anti-proliferative and anti-angiogenic strategies for cancer.
Bar J; Onn A
Expert Opin Pharmacother; 2008 Apr; 9(5):701-15. PubMed ID: 18345949
[TBL] [Abstract][Full Text] [Related]
31. Regarding: Rosenthal DI, Glatstein E. "We've Got a Treatment, but What's the Disease?" The Oncologist 1996;1.
Lunsford LD; Flickinger JC; Larson D
Oncologist; 1997; 2(1):59-61. PubMed ID: 10388030
[TBL] [Abstract][Full Text] [Related]
32. Anti-angiogenic gene therapy of cancer: current status and future prospects.
Persano L; Crescenzi M; Indraccolo S
Mol Aspects Med; 2007 Feb; 28(1):87-114. PubMed ID: 17306361
[TBL] [Abstract][Full Text] [Related]
33. Implications of the new biology for therapy in breast cancer.
Sledge GW
Semin Oncol; 1996 Feb; 23(1 Suppl 2):76-81. PubMed ID: 8614850
[TBL] [Abstract][Full Text] [Related]
34. Design and development of polymer conjugates as anti-angiogenic agents.
Segal E; Satchi-Fainaro R
Adv Drug Deliv Rev; 2009 Nov; 61(13):1159-76. PubMed ID: 19699248
[TBL] [Abstract][Full Text] [Related]
35. Targeting multiple signaling pathways as a strategy for managing prostate cancer: multifocal signal modulation therapy.
McCarty MF
Integr Cancer Ther; 2004 Dec; 3(4):349-80. PubMed ID: 15523106
[TBL] [Abstract][Full Text] [Related]
36. VEGF signaling inhibitors: more pro-apoptotic than anti-angiogenic.
Epstein RJ
Cancer Metastasis Rev; 2007 Dec; 26(3-4):443-52. PubMed ID: 17786538
[TBL] [Abstract][Full Text] [Related]
37. Microtubule-targeting agents in angiogenesis: where do we stand?
Pasquier E; Honoré S; Braguer D
Drug Resist Updat; 2006; 9(1-2):74-86. PubMed ID: 16714139
[TBL] [Abstract][Full Text] [Related]
38. [Role of angiogenesis in the growth and progression of tumors. Treatment with angiogenesis inhibitors: from promising results in experimental animal models to the reality of clinical use].
Plavetić ND; Letilović T; Vrbanec D
Lijec Vjesn; 2003; 125(9-10):260-5. PubMed ID: 15038217
[TBL] [Abstract][Full Text] [Related]
39. [Angiogenesis and antiangiogenic cancer therapy].
Pour L; Hájek R; Buchler T; Maisnar V; Smolej L
Vnitr Lek; 2004 Dec; 50(12):930-8. PubMed ID: 15717808
[TBL] [Abstract][Full Text] [Related]
40. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
